Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Two-arm Parallel Group, No Treatment Group-controlled, Multicenter Phase III Study to Evaluate the Safety and Efficacy of Saizen® 0.067 mg/kg/Day Subcutaneous Injection in Children With Idiopathic Short Stature

NCT01746862 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01746862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01746862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Two-arm Parallel Group, No Treatment Group-controlled, Multicenter Phase III Study to Evaluate the Safety and Efficacy of Saizen® 0.067 mg/kg/Day Subcutaneous Injection in Children With Idiopathic Short Stature
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2012
Completion date
March 31, 2015
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic short stature